The results have been shared at the American Heart Association (AHA) Late-Breaking Scientific Session and published simultaneously in the Lancet. Implementing thestudy’s strategy in routine clinical practice, has the opportunity to significantly reduce all cause deaths or heart failure readmissions and increase quality of life for more heart failure patients, evaluated after six months, compared to current patient management practices. The study, which includes utilisation of the Roche Elecsys NT-proBNP biomarker, was terminated early for superior efficacy in the active arm of the study versus the usual standard of care, as it was considered unethical to continue with usual care. The Roche Elecsys ® NT- proBNP biomarker is an integral part of the treatment strategy, comprising rapid up-titration and close follow up after a n acute heart failure admissionīasel, 9 November 2022 - Roche (SIX: RO, ROG OTCQX: RHHBY) today announced publication of the Safety, Tolerability and Efficacy of Rapid Optimization of Heart Failure (STRONG-HF) study in patients hospitalised for acute heart failure. Rapid, simultaneous up-titration of therapies, and close follow-up, led to increased patient quality of life. STRONG-HF study primary outcomes showed significant reduction of all cause death or acute heart failure readmissions, at day 180, when the study strategy was implemented
0 kommentar(er)
